Amyloids for inflammation

Researchers at Stanford University have found that systemic treatment with b-amyloid peptides can reduce inflammation and reverse paralysis in mouse models of multiple sclerosis.1 Cardinal Therapeutics Inc. has licensed the work and now is developing anti-inflammatory amyloids. The company hopes to select a specific indication and name a lead compound by year end.

b-Amyloid (Ab) is the plaque-forming protein linked to Alzheimer's disease (AD) pathology. Past studies by academic groups have shown that b-amyloid is upregulated in multiple sclerosis (MS) lesions.2,3 However, the role of b-amyloid in MS was not well defined, and it was unclear whether it was harmful or protective.

Read the full 1010 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE